TB-500 (Thymosin Beta-4) · Research brief

TB-4 Dosage Protocol Guide — Real Peptides

Real Peptides Research TeamEditorial

Updated April 3, 202610 min read

52 WORDS

Short answer

Key takeaways

TB-4 has a plasma half-life of approximately 10 hours, requiring twice-weekly injections during loading phases to maintain therapeutic tissue concentrations.
Standard loading protocols use 4–6mg weekly for 4–6 weeks, split into two subcutaneous injections, followed by maintenance at 2–4mg weekly or biweekly.
Reconstitution must be performed with bacteriostatic water at precise ratios. A 5mg vial with 2mL water yields 2.5mg/mL, requiring 0.8mL for a 2mg dose.
Unreconstituted lyophilized TB-4 must be stored at −20°C; once reconstituted, refrigerate at 2–8°C and use within 28 days to prevent degradation.
TB-4 works by binding G-actin to promote cellular migration and angiogenesis through VEGF upregulation. Not through receptor-mediated signaling like GLP-1 agonists.
Temperature excursions above 8°C cause irreversible peptide denaturation. Visual clarity of the solution does not indicate biological potency.

Most TB-4 dosage protocols fail before the first injection. Not from incorrect dosing, but from storage errors that denature the peptide structure before it ever reaches tissue. A single temperature excursion during shipping or reconstitution can render thymosin beta-4 biologically inactive, and neither visual inspection nor home testing can detect the loss. We've guided hundreds of researchers through this exact process, and the difference between results and wasted investment comes down to three factors: dosage accuracy, reconstitution sterility, and temperature control from delivery to administration.

What is the correct TB-4 dosage protocol for research applications?

TB-4 dosage protocols typically range from 2mg to 10mg per week depending on research objectives, with most tissue repair studies using 4–6mg weekly split into two subcutaneous injections. Clinical research has documented effective plasma concentrations at 750mcg twice weekly for 4–6 weeks, followed by maintenance phases at 2–4mg monthly. The active peptide. Thymosin beta-4. Has a half-life of approximately 10 hours in circulation, requiring frequent dosing during loading phases to maintain therapeutic tissue concentrations.

Yes, TB-4 produces measurable biological effects at research-verified dosages. But the compound's short circulating half-life and sensitivity to temperature degradation mean that dosing accuracy and storage discipline matter more than the protocol itself. The peptide works by upregulating actin sequestration, promoting angiogenesis through vascular endothelial growth factor (VEGF) pathways, and modulating inflammatory cytokine expression. The rest of this TB-4 dosage protocol guide covers reconstitution procedures, injection timing strategies, dosage ranges across research applications, storage requirements that preserve peptide integrity, and the mistakes that compromise bioavailability before the compound ever reaches tissue.

Understanding TB-4 Mechanism and Dosage Rationale

TB-4 functions through actin-binding mechanisms that influence cellular migration, differentiation, and tissue remodeling. Not through receptor-mediated signaling like growth hormone secretagogues. The peptide binds monomeric G-actin, preventing polymerization and creating a pool of unpolymerized actin available for rapid cytoskeletal reorganization during cell migration and wound healing. This mechanism explains why TB-4 shows tissue repair effects in models studying cardiac injury, dermal wounds, and musculoskeletal damage. The compound facilitates the cellular movement required for tissue regeneration.

Dosage protocols reflect this mechanism. Loading phases use higher frequencies (750mcg to 2mg twice weekly) to saturate tissue pools rapidly, establishing baseline actin-sequestering activity across target tissues. Maintenance protocols reduce frequency to once weekly or biweekly because the peptide's biological effects. Upregulation of matrix metalloproteinases, promotion of endothelial cell migration, modulation of inflammatory mediators. Persist beyond its 10-hour plasma half-life. The tissue-level half-life appears considerably longer than circulating half-life, though precise pharmacokinetic data in humans remains limited.

Research models have used TB-4 dosages ranging from 6mg/kg in rodent studies to fixed human-equivalent doses of 2–10mg weekly in observational case series. The University of California published findings in 2011 showing that TB-4 administration improved left ventricular function in a porcine myocardial infarction model at doses equivalent to approximately 30mg weekly in a 70kg human. Significantly higher than typical research protocols. Most current TB-4 dosage protocol frameworks use 4–6mg weekly as a middle range, balancing theoretical efficacy against cost and injection frequency.

The peptide's MW (molecular weight) is 4.9 kDa, and it contains 43 amino acids in its biologically active sequence. Reconstitution requires bacteriostatic water at a 1:1 or 2:1 dilution depending on vial concentration. Most lyophilized TB-4 is supplied as 2mg, 5mg, or 10mg per vial. A 5mg vial reconstituted with 2mL bacteriostatic water yields a concentration of 2.5mg/mL, meaning a 2mg dose requires 0.8mL (80 units on a U-100 insulin syringe). Dosing accuracy depends entirely on reconstitution math. Errors at this stage cascade into either underdosing (no biological effect) or waste through overdosing.

TB-4 Dosage Protocol by Research Application

Research objectives determine TB-4 dosing structure. Tissue repair models use different protocols than cardiovascular or dermatological studies. The following dosage frameworks reflect published research and observational case documentation, not clinical prescribing guidelines. TB-4 is not FDA-approved for human therapeutic use. All references are to research contexts only.

Soft tissue injury and recovery models typically employ a loading phase of 4–6mg weekly (split into two 2–3mg injections) for 4–6 weeks, followed by a maintenance phase of 2–4mg weekly or biweekly for an additional 4–8 weeks. This structure mirrors the natural wound healing timeline. The loading phase corresponds to the inflammatory and proliferative phases (days 0–21 post-injury), while maintenance dosing supports the remodeling phase (weeks 3–12). Subcutaneous injection near the injury site is common, though systemic subcutaneous administration (abdominal or deltoid) produces similar plasma concentrations due to the peptide's systemic distribution.

Cardiovascular research applications have used higher cumulative doses. A 2010 study in the Journal of Cardiovascular Pharmacology documented TB-4 administration at 6mg twice weekly for four weeks in a post-myocardial infarction animal model, demonstrating improved angiogenesis and reduced scar tissue formation. Human-equivalent dosing extrapolated from this model suggests 8–12mg weekly during acute phases, though no randomized controlled trials in humans exist to validate safety or efficacy at these levels. The peptide's proposed mechanism in cardiac tissue involves activation of epicardial progenitor cells and upregulation of VEGF, both of which require sustained tissue concentrations.

Dermatological and cosmetic research uses lower cumulative doses. 2–4mg weekly for 6–12 weeks. Often combined with other regenerative peptides like GHK-Cu or BPC-157. The rationale is collagen remodeling and fibroblast migration rather than acute injury repair, which requires less aggressive dosing. Some protocols use TB-4 in a cyclical pattern (4 weeks on, 2 weeks off) to prevent downregulation of endogenous thymosin expression, though evidence for this concern is theoretical rather than empirical.

Neurological research models exploring TB-4's potential in traumatic brain injury or stroke have employed bolus dosing. Single high-dose administrations (10–30mg) within hours of the neurological event, followed by weekly maintenance. The hypothesis is that early high-dose administration promotes oligodendrocyte progenitor migration and axonal sprouting during the acute injury window. These protocols are experimental and based primarily on rodent studies. Translating effective rodent doses to human equivalents involves significant uncertainty due to metabolic rate differences.

All TB-4 dosage protocol structures share common elements: an initial loading phase with higher frequency or dose, a transition to maintenance dosing, and subcutaneous administration. Intramuscular injection is less common due to slower absorption kinetics and increased injection site discomfort. Intravenous administration has been used in research settings but offers no bioavailability advantage over subcutaneous routes and requires sterile compounding infrastructure not available in most research environments.

TB-4 Dosage Protocol: Reconstitution, Storage, and Administration Comparison

Protocol Element	Loading Phase (Weeks 1–4)	Maintenance Phase (Weeks 5–12)	Storage and Handling	Bottom Line
Typical Dosage Range	4–6mg weekly, split into 2 injections (e.g., 2mg Monday, 2mg Thursday)	2–4mg weekly or biweekly as single injection	Unreconstituted: store at −20°C; reconstituted: 2–8°C, use within 28 days	Higher loading doses establish tissue saturation; maintenance sustains effects without receptor downregulation risk
Injection Frequency	Twice weekly (every 3–4 days) to maintain plasma levels above threshold	Once weekly or biweekly depending on response and research timeline	Avoid freeze-thaw cycles. Aliquot if necessary before freezing	Frequent early dosing compensates for short 10-hour circulating half-life
Reconstitution Volume	2mL bacteriostatic water per 5mg vial = 2.5mg/mL concentration	Same. Consistency in concentration prevents dosing errors	Inject bacteriostatic water slowly down vial wall, never shake, swirl gently until dissolved	Correct dilution math is non-negotiable. Errors here mean wasted peptide or ineffective dosing
Injection Route	Subcutaneous (abdominal, deltoid, or near injury site if localized study)	Subcutaneous, systemic sites preferred for maintenance	Rotate injection sites to prevent lipohypertrophy or tissue irritation	Subcutaneous absorption reaches peak plasma in 30–60 minutes; IM offers no advantage
Temperature Control	Ship with cold packs; transfer to freezer immediately upon receipt	After reconstitution, refrigerate. Never refreeze	Any excursion above 8°C risks denaturation; visual clarity is not a potency indicator	Temperature discipline matters more than dosage precision. Heat-damaged TB-4 is biologically inactive
Contamination Risk	Use sterile technique. Alcohol swabs, clean work surface, no touch transfer	Always use fresh needle for drawing and separate needle for injection	Bacteriostatic water inhibits bacterial growth but does not sterilize; aseptic technique required	Contaminated vials can cause injection site reactions or systemic infection

What If: TB-4 Dosage Protocol Scenarios

What If I Accidentally Left Reconstituted TB-4 Out of the Refrigerator Overnight?

Discard the vial. Do not attempt to salvage it by refrigerating after the fact. TB-4's peptide bonds begin breaking down at temperatures above 8°C, and the degradation process is irreversible. Even if the solution appears clear and unchanged, the biological activity has been compromised. The cost of replacing one vial is far lower than the cost of continuing a research protocol with inactive compound and attributing lack of results to ineffective dosing rather than degraded product.

What If I'm Not Seeing Expected Results After Four Weeks at 4mg Weekly?

First, verify reconstitution and storage procedures. Degraded peptide is the most common cause of non-response. Second, consider increasing dose to 6mg weekly split into two injections, or extending the loading phase to six weeks before transitioning to maintenance. TB-4's effects are dose-dependent and cumulative. Some research models required 8–10 weeks before measurable tissue-level changes. If sourcing from a compounding provider, request third-party purity testing (HPLC or mass spectrometry) to verify actual peptide content matches the label claim.

What If I Miss a Scheduled Injection During the Loading Phase?

Administer the missed dose as soon as you remember if fewer than 48 hours have passed, then resume your regular schedule. If more than 48 hours have passed, skip the missed dose and continue with the next scheduled injection. Do not double-dose to compensate. Missing a single injection during a 4–6 week loading phase has minimal impact on cumulative tissue exposure, but repeated missed doses effectively convert a loading protocol into a maintenance protocol, delaying saturation.

What If I Want to Combine TB-4 with Other Peptides Like BPC-157 or GHK-Cu?

TB-4 is commonly stacked with BPC-157 in tissue repair research models due to complementary mechanisms. TB-4 promotes cellular migration and angiogenesis, while BPC-157 modulates growth factor expression and collagen synthesis. Standard stacking protocols administer both peptides at their individual recommended doses (TB-4 at 4–6mg weekly, BPC-157 at 250–500mcg daily) via separate injections. GHK-Cu can be added for additional collagen remodeling effects. There is no evidence of negative interactions between these peptides, though no formal interaction studies exist.

The Evidence-Based Truth About TB-4 Dosage Protocols

Here's the honest answer: TB-4 dosage protocols are built almost entirely on animal research, case reports, and theoretical extrapolation. Not on randomized controlled trials in humans. The peptide has never completed Phase III clinical trials for any indication, which means every dosing recommendation you encounter is educated guesswork based on rodent pharmacokinetics, porcine cardiac models, and anecdotal human use. That doesn't mean TB-4 is ineffective. The mechanism is well-established, and the preclinical data is compelling. But it does mean that 'optimal dosing' is a moving target shaped more by cost constraints and injection tolerance than by evidence-based therapeutic windows.

The 4–6mg weekly loading dose didn't emerge from dose-finding studies. It emerged from researchers attempting to balance the cost of peptide (TB-4 is expensive) against the need for sustained tissue exposure. The twice-weekly injection frequency is a response to the 10-hour plasma half-life, but no one has definitively established whether tissue-level concentrations follow the same decay curve. Some researchers argue for daily microdosing (500mcg daily) instead of bolus dosing, others argue for higher single doses (10mg once weekly), and the truth is no one has comparative data to settle the question.

What we do know: TB-4 works through actin sequestration, it promotes angiogenesis in every model tested, and it shows reproducible tissue repair effects in controlled animal studies. The dosage protocol you choose matters less than the integrity of your storage, reconstitution, and injection technique. A researcher using 2mg weekly with flawless cold chain management will see better results than a researcher using 10mg weekly with temperature-compromised peptide. Focus on the basics. Sterile reconstitution, refrigerated storage, accurate dosing math, and consistent injection timing. And the protocol will perform as well as current evidence allows.

Sourcing TB-4 with Verifiable Purity Standards

TB-4 quality varies dramatically between suppliers, and purity claims on labels are often aspirational rather than verified. Real Peptides addresses this through third-party testing and transparent Certificate of Analysis (CoA) documentation for every batch. Our TB-500 Thymosin Beta-4 is synthesized using solid-phase peptide synthesis with exact amino acid sequencing, then verified via high-performance liquid chromatography (HPLC) to confirm >98% purity before release.

The difference between 98% purity and 85% purity is not subtle. Impurities can include truncated peptide sequences, synthesis byproducts, or degradation fragments that occupy vial volume without contributing biological activity. A vial labeled '5mg TB-4' at 85% purity contains only 4.25mg of active peptide, meaning every dose is underdosed by 15% relative to protocol. Over a 12-week research timeline, that gap compounds into the equivalent of missing two full weeks of dosing.

We've worked with researchers across tissue repair, regenerative medicine, and performance optimization studies, and the most common protocol error isn't dosage. It's peptide sourcing. Reconstitution technique and storage discipline mean nothing if the peptide degraded during manufacturing or shipping. Every peptide we supply ships with cold packs and arrives within 48 hours to minimize temperature exposure. You can explore our full range of research-grade compounds at our peptide collection, where quality control is non-negotiable and purity documentation is standard.

TB-4 dosage protocol success depends on one principle: precision at every step. Precise reconstitution math, precise injection timing, precise temperature control, and precise peptide purity. Miss any one of those variables, and the entire protocol underperforms. Not because the science is wrong, but because execution failed before biology had a chance to respond.

Questions

TB-4 binds monomeric G-actin and prevents its polymerization, creating a pool of unpolymerized actin available for rapid cytoskeletal reorganization during cellular migration. This mechanism facilitates the movement of fibroblasts, endothelial cells, and keratinocytes into damaged tissue. TB-4 also upregulates vascular endothelial growth factor (VEGF), promoting angiogenesis, and modulates inflammatory cytokine expression to reduce excessive inflammation during the wound healing process.

TB-4 has shown effects in both acute and chronic injury models, though the dosing structure differs. Acute injuries typically use higher-frequency loading protocols (4–6mg weekly for 4–6 weeks) to capitalize on the natural inflammatory and proliferative wound healing phases. Chronic injuries — those present for months or years — may require extended protocols (12+ weeks) with maintenance dosing (2–4mg weekly) because tissue remodeling in chronic conditions occurs more slowly and with greater fibrotic resistance.

Research-grade TB-4 with verified >98% purity typically costs $80–$150 per 5mg vial depending on supplier and batch size. Lower-purity versions (85–90% verified, or unverified purity claims) can be found for $40–$70 per vial. The apparent savings disappear when you account for reduced active peptide content — an 85% pure 5mg vial contains only 4.25mg of active TB-4, effectively increasing cost per milligram of actual compound. Additionally, impurities increase the risk of injection site reactions and reduce reproducibility of results.

Reconstituted TB-4 stored at 2–8°C in bacteriostatic water maintains biological activity for approximately 28 days, after which peptide degradation accelerates. Some researchers extend this to 60 days by using sterile saline instead of bacteriostatic water and aliquoting into single-use vials to minimize repeated punctures and contamination risk. Beyond 28 days, potency loss is measurable but variable — there is no reliable way to test potency at home, so adhering to the 28-day guideline prevents underdosing due to degraded product.

TB-500 is a synthetic version of the active region of thymosin beta-4 (TB-4), specifically the 17–23 amino acid fragment responsible for actin binding. Full-sequence TB-4 contains 43 amino acids and includes additional bioactive regions that may influence immune modulation and cellular differentiation beyond what TB-500 provides. Most research uses TB-500 due to lower synthesis cost, but some models suggest full-sequence TB-4 has broader biological activity. The dosing protocols are nearly identical because both function primarily through the same actin-sequestering mechanism.

Subcutaneous injection into abdominal tissue, deltoid, or thigh produces equivalent systemic bioavailability — TB-4 distributes systemically regardless of injection location. Some researchers inject near the injury site (e.g., peritendinous for tendon injuries) based on the hypothesis that local concentration may enhance tissue-specific uptake, though pharmacokinetic data supporting this approach is limited. Rotating injection sites prevents lipohypertrophy and tissue irritation, particularly during protocols lasting 8–12 weeks with twice-weekly injections.

Most TB-4 dosage protocols use continuous administration during the 8–12 week treatment window rather than cycling. The rationale for cycling (e.g., 4 weeks on, 2 weeks off) is to prevent downregulation of endogenous thymosin beta-4 production, but there is no published evidence that exogenous TB-4 suppresses natural production in the way that exogenous testosterone suppresses endogenous testosterone synthesis. Tissue repair processes benefit from sustained peptide exposure, making continuous protocols more common in research models.

The three most common errors are improper reconstitution math leading to incorrect dosing, failure to maintain cold chain storage (allowing temperature excursions above 8°C), and using peptide from suppliers without third-party purity verification. A less obvious error is injecting air into the vial during reconstitution or drawing — the resulting positive pressure can pull contaminants back through the needle during subsequent draws, compromising sterility. Another frequent mistake is discarding cloudy or particulate solutions without recognizing that some precipitation is normal when refrigerated and resolves at room temperature.

TB-4 and BPC-157 work through different mechanisms and are often stacked rather than used as alternatives. TB-4 promotes cellular migration and angiogenesis via actin binding and VEGF upregulation, while BPC-157 enhances growth factor receptor expression (particularly VEGF receptors) and modulates nitric oxide pathways to improve blood flow. Research models combining both peptides at standard doses (TB-4 at 4–6mg weekly, BPC-157 at 250–500mcg daily) report faster tissue repair timelines than either compound alone, though no head-to-head randomized trials exist.

Loading phases (higher dose or frequency for the first 4–6 weeks) are designed to saturate tissue pools of actin-binding peptide quickly, establishing baseline biological activity before transitioning to lower maintenance doses. Starting directly at maintenance levels (2–4mg weekly) will eventually reach similar tissue concentrations but extends the time to measurable effect by several weeks. For acute injury models where early intervention matters, loading protocols are standard. For chronic conditions or preventive applications, starting at maintenance dose is a reasonable cost-saving approach.

Lyophilized TB-4 should be shipped with cold packs or gel packs maintaining temperatures between 2–8°C, though brief excursions to 15–20°C during transit (under 24 hours) are generally tolerable. Temperatures above 25°C for extended periods (more than 12 hours) begin irreversible peptide degradation. Upon receipt, transfer immediately to freezer storage at −20°C if the vial will not be used within one week. Once reconstituted, refrigerate at 2–8°C continuously — any warming above 8°C compromises stability, and refreezing after reconstitution destroys peptide structure entirely.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA